JP7383030B2 - Ｔｙｋ２キナーゼ阻害剤 - Google Patents
Ｔｙｋ２キナーゼ阻害剤 Download PDFInfo
- Publication number
- JP7383030B2 JP7383030B2 JP2021543577A JP2021543577A JP7383030B2 JP 7383030 B2 JP7383030 B2 JP 7383030B2 JP 2021543577 A JP2021543577 A JP 2021543577A JP 2021543577 A JP2021543577 A JP 2021543577A JP 7383030 B2 JP7383030 B2 JP 7383030B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- tyk2
- compounds
- disease
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816369.1 | 2018-10-08 | ||
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514799A JP2022514799A (ja) | 2022-02-15 |
| JP2022514799A5 JP2022514799A5 (enExample) | 2022-09-28 |
| JP7383030B2 true JP7383030B2 (ja) | 2023-11-17 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543577A Active JP7383030B2 (ja) | 2018-10-08 | 2019-10-07 | Ｔｙｋ２キナーゼ阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12187716B2 (enExample) |
| EP (1) | EP3864009B1 (enExample) |
| JP (1) | JP7383030B2 (enExample) |
| KR (1) | KR102844196B1 (enExample) |
| CN (1) | CN113056456B (enExample) |
| AU (1) | AU2019359320B2 (enExample) |
| BR (1) | BR112021006424A2 (enExample) |
| CA (1) | CA3111049A1 (enExample) |
| DK (1) | DK3864009T3 (enExample) |
| ES (1) | ES3021420T3 (enExample) |
| FI (1) | FI3864009T3 (enExample) |
| GB (1) | GB201816369D0 (enExample) |
| IL (1) | IL281599B2 (enExample) |
| MX (1) | MX2021003929A (enExample) |
| PL (1) | PL3864009T3 (enExample) |
| PT (1) | PT3864009T (enExample) |
| SG (1) | SG11202102490TA (enExample) |
| WO (1) | WO2020074461A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016529264A (ja) | 2013-09-03 | 2016-09-23 | サリウム リミテッド | 医薬化合物 |
| WO2018073438A1 (en) | 2016-10-21 | 2018-04-26 | Sareum Limited | Pharmaceutical compounds |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| NZ522696A (en) | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| MXPA03003868A (es) | 2000-10-30 | 2003-07-28 | Janssen Pharmaceutica Nv | Inhibidores de tripeptidil peptidasa. |
| EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| PL1684750T3 (pl) | 2003-10-23 | 2010-10-29 | Ab Science | 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| EP1932833B1 (en) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| ATE480525T1 (de) | 2006-05-12 | 2010-09-15 | Ab Science | Neues verfahren zur synthese von 2- aminooxazolverbindungen |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2166846B1 (en) | 2007-06-20 | 2012-10-17 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2730010A1 (en) | 2008-07-09 | 2010-01-14 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| JP2013522267A (ja) | 2010-03-17 | 2013-06-13 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾピリジン化合物、組成物、および使用法 |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2013055645A1 (en) | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| DK2634185T3 (en) * | 2012-03-02 | 2016-03-21 | Sareum Ltd | Tyk2 kinase inhibitors |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| AU2013341186B2 (en) | 2012-11-08 | 2017-03-30 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| JP6310767B2 (ja) | 2014-05-13 | 2018-04-11 | 日本電子株式会社 | 自動分析装置及びノズル洗浄方法 |
| NO2721710T3 (enExample) | 2014-08-21 | 2018-03-31 | ||
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en not_active Ceased
- 2019-10-07 ES ES19794095T patent/ES3021420T3/es active Active
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 PL PL19794095.0T patent/PL3864009T3/pl unknown
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/ja active Active
- 2019-10-07 KR KR1020217013504A patent/KR102844196B1/ko active Active
- 2019-10-07 DK DK19794095.0T patent/DK3864009T3/da active
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/pt unknown
- 2019-10-07 US US17/283,151 patent/US12187716B2/en active Active
- 2019-10-07 EP EP19794095.0A patent/EP3864009B1/en active Active
- 2019-10-07 FI FIEP19794095.0T patent/FI3864009T3/fi active
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/es unknown
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/zh active Active
- 2019-10-07 IL IL281599A patent/IL281599B2/en unknown
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
- 2019-10-07 PT PT197940950T patent/PT3864009T/pt unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016529264A (ja) | 2013-09-03 | 2016-09-23 | サリウム リミテッド | 医薬化合物 |
| WO2018073438A1 (en) | 2016-10-21 | 2018-04-26 | Sareum Limited | Pharmaceutical compounds |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3021420T3 (en) | 2025-05-26 |
| CA3111049A1 (en) | 2020-04-16 |
| MX2021003929A (es) | 2021-06-04 |
| BR112021006424A2 (pt) | 2021-07-06 |
| GB201816369D0 (en) | 2018-11-28 |
| EP3864009B1 (en) | 2025-02-19 |
| CN113056456B (zh) | 2023-06-13 |
| PL3864009T3 (pl) | 2025-04-22 |
| CN113056456A (zh) | 2021-06-29 |
| FI3864009T3 (fi) | 2025-03-24 |
| KR102844196B1 (ko) | 2025-08-07 |
| US20210387981A1 (en) | 2021-12-16 |
| KR20210076036A (ko) | 2021-06-23 |
| US12187716B2 (en) | 2025-01-07 |
| PT3864009T (pt) | 2025-04-23 |
| DK3864009T3 (da) | 2025-03-17 |
| IL281599B1 (en) | 2024-06-01 |
| WO2020074461A1 (en) | 2020-04-16 |
| SG11202102490TA (en) | 2021-04-29 |
| IL281599A (en) | 2021-05-31 |
| JP2022514799A (ja) | 2022-02-15 |
| EP3864009A1 (en) | 2021-08-18 |
| IL281599B2 (en) | 2024-10-01 |
| AU2019359320A1 (en) | 2021-03-18 |
| AU2019359320B2 (en) | 2024-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11673870B2 (en) | Pharmaceutical compounds | |
| JP6239118B2 (ja) | 医薬化合物 | |
| CN110191887B (zh) | IL-12、IL-23和/或IFN-α的咪唑并哒嗪调节剂 | |
| KR102844196B1 (ko) | Tyk2 키나제 억제제 | |
| JP7660135B2 (ja) | Ｔｙｋ２阻害剤の結晶形態 | |
| US20130203803A1 (en) | Azaindazole Amide Compounds As CCR1 Receptor Antagonists | |
| RU2805932C2 (ru) | Фармацевтические соединения | |
| HK40048146B (en) | Tyk2 kinase inhibitors | |
| HK40048146A (en) | Tyk2 kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220915 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220915 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231013 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231026 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231107 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7383030 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |